Rigel Pharmaceuticals Inc

Despite the medium- and long-term bullish structure under a Stage 2 advance, extreme overbought conditions and an active Bullish Exhaustion pattern signal waning upside follow-through; deferred execution is advised, waiting for a pullback into the rising EMA support zone.

• ↑Q1 sales $54.9M, +26% YoY, driven by Tavalisse growth
• ↑Maintains 2026 revenue guidance of $275–290M with sequential lift
• ↓High stock volatility and leverage raise financial stability concerns